Autoimmune Diseases
CGEMCullinan ManagementCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Velinotamig (BCMAxCD3) (T Cell Engager) in Autoimmune Diseases. The expected timing is based on the latest available company guidance and may change.
11/06/25:- Genrix to start velinotamig autoimmune Ph1 trial in China by end of 2025. 01/08/26:- Genrix initiated velinotamig autoimmune Ph1 in China Dec 2025; initial clinical data expected Q4 2026. 03/10/26:- Genrix velinotamig autoimmune Ph1 in China enrolling; initial clinical data expected Q4 2026. 05/07/26:- Genrix autoimmune Ph1 enrolling in China; initial SLE multi-dose regimen data expected in Q4 2026. 05/26/26:- Immunology Day June 10, 2026 to share Genrix China first multi-dose cohort data. 06/06/26:- Initial velinotamig autoimmune Ph1 clinical data will be shared June 10, 2026. 08/06/26:- Genrix Ph1/2 SLE responses reported; additional data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.